Vanguard Global Advisers
ATRA icon

Vanguard Global Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Vanguard Global Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Hold
1,456
– – ﹤0.01% 3378
2026
Q1 		$6.89K Buy
+1,456
New +$8.88K ﹤0.01% 3526

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Global Advisers's ATRA Position: Q2 2026 in Review

Vanguard Global Advisers held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 1,456 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

Vanguard Global Advisers first reported a position in ATRA in Q1 2026 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Vanguard Global Advisers held 1,456 shares of Atara Biotherapeutics worth $16.7K as of Q2 2026.
  • Vanguard Global Advisers left its Atara Biotherapeutics share count unchanged in Q2 2026.
  • Atara Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3378 holding.
  • Vanguard Global Advisers first reported a position in Atara Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.